Itraconazole - Mayne Pharma

Drug Profile

Itraconazole - Mayne Pharma

Alternative Names: Itragerm; Itraisdin; Lozanoc; Mytra; Subacap; SUBA™-itraconazole

Latest Information Update: 24 Oct 2016

Price : $50

At a glance

  • Originator Mayne Pharma Group
  • Developer HedgePath Pharmaceuticals; Mayne Pharma Group
  • Class Antifungals; Azoles; Chlorobenzenes; Piperazines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Hedgehog cell-signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Mycoses

Highest Development Phases

  • Marketed Mycoses
  • Phase II Basal cell cancer

Most Recent Events

  • 20 Oct 2016 Second interim efficacy events data from a phase IIb trial in Basal cell cancer released by HedgePath Pharmaceuticals
  • 03 Aug 2016 Interim efficacy and adverse events data from a phase IIb trial in Basal cell cancer released by HedgePath Pharmaceuticals
  • 02 Jun 2016 Itraconazole receives Orphan Drug status for Basal cell cancer (in patients with basal cell cancer nevus syndrome) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top